Skip to main content

Table 2 Prognostic factors

From: The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents

Univariable
CpG sites
 Per methylated site in Sseq 0.95 (< 0.01/0.93–0.97) 0.95 (< 0.01/0.94–0.97)
Age (years)
 Per year 1.02 (< 0.01/1.00–1.03) 1.02 (< 0.01/1.01–1.04)
KPS
  <80 versus ≥ 80 2.00 (< 0.01/1.36–2.94) 2.99 (< 0.01/2.01–4.45)
Tumor side
 Left versus right 1.25 (n.s./0.95–1.64) 1.16 (n.s./0.87–1.53)
Tumor location
 Lobar versus other 0.90 (n.s./0.68–1.20) 0.82 (n.s./0.61–1.1)
MSP status
 Positive versus negative 0.44 (< 0.01/0.33–0.60) 0.45 (< 0.01/ 0.34–0.61)
Surgical treatment
 OTR versus biopsy 0.64 (< 0.01/0.48–0.86) 0.59 (< 0.01/ 0.45–0.80)
Multivariable
CpG sites
 Per methylated site in Sseq 0.96 (< 0.01/0.93–0.99) 0.95 (< 0.01/0.92–0.99)
Age (years)
P er year 1.02 (< 0.01/1.01–1.04) 1.03 (< 0.01/1.02–1.05)
KPS
 < 80 versus ≥ 80 1. 94 (n.s./1.30–2.91) 2.88 (< 0.01/1.90–4.36)
Tumor location
 Lobar versus other 1.04 (n.s./0.74–1.45) 1.08 (n.s./0.76–1.53)
MSP status
 Positive versus negative 0.77 (n.s./0.44–1.34) 0.68 (n.s./0.37–1.26)
Surgical treatment
 OTR versus biopsy 0.75 (n.s./0.54–1.03) 0.63 (< 0.01/0.44–0.89)